Pirazzoli, Valentina <br/><br/>
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.  [electronic resource] 

 -  Cell reports  May 2014 
 - 999-1008 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2211-1247 
<br/><br/><label>Standard No.: </label>10.1016/j.celrep.2014.04.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenocarcinoma of Lung<br/>Afatinib<br/>Animals<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Cetuximab<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--genetics<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Mechanistic Target of Rapamycin Complex 1<br/>Mice<br/>Mice, Nude<br/>Mice, Transgenic<br/>Multiprotein Complexes--metabolism<br/>Mutation<br/>Quinazolines--administration & dosage<br/>Random Allocation<br/>TOR Serine-Threonine Kinases--metabolism<br/>Xenograft Model Antitumor Assays